09:26 AM EST, 11/04/2025 (MT Newswires) -- Tango Therapeutics ( TNGX ) reported Q3 net income Tuesday of $0.14 per diluted share, swinging from a loss of $0.27 a year earlier.

One analyst polled by FactSet expected a loss of $0.05.

Revenue for the quarter ended Sept. 30 was $53.8 million, up from $11.6 million a year earlier.

Analysts surveyed by FactSet expected $53.8 million.

The company said it had $152.8 million in cash, cash equivalents and marketable securities as of Sept. 30, in addition to $212 million in net proceeds from a recent common stock offering, which is expected to fund operations into 2028.